article thumbnail

Circulating bone morphogenetic protein 10 as a novel marker of atrial stress and remodelling in heart failure

Heart BMJ

Background We evaluated the potential of circulating bone morphogenetic protein 10 (BMP10) as a biomarker for atrial stress and remodelling in patients with heart failure (HF), in comparison to N-terminal pro-B-type natriuretic peptide (NT-proBNP). We also assessed the predictive value of BMP10 for adverse clinical outcomes.

article thumbnail

The human heart may have a hidden ability to repair itself

Medical Xpress - Cardiology

After severe heart failure, the ability of the heart to heal by forming new cells is very low. However, after receiving treatment with a supportive heart pump, the capacity of a damaged heart to repair itself with new muscle cells becomes significantly higher, even higher than in a healthy heart.

article thumbnail

Fast Degradation of MecciRNAs by SUPV3L1/ELAC2 Provides a Novel Opportunity to Tackle Heart Failure With Exogenous MecciRNA

Circulation

Circulation, Ahead of Print. Mitochondria dysfunctions are well-known to participate in heart failure (HF). Mitochondria dysfunctions are well-known to participate in heart failure (HF). BACKGROUND:Circular RNAs derived from both nuclear and mitochondrial genomes are identified in animal cells.

article thumbnail

Study highlights potential for using TMAO—a digestive by-product—to predict heart failure risk

Medical Xpress - Cardiology

New Cleveland Clinic and Tufts University research shows that elevated levels of the gut microbiome trimethylamine N-oxide (TMAO) pathway led to a higher risk of heart failure independent of other risk factors, according to a study of two large National Institutes of Health cohorts.

article thumbnail

Circulating miRNA-486 as a novel diagnostic biomarker for right ventricular remodeling

Frontiers in Cardiovascular Medicine

The diagnostic power of the candidate miRNA was further validated in 100 patients [20 with adaptive RV pressure overload; 20 with maladaptive RV pressure overload; 20 with left heart failure (LHF); 19 with left ventricular hypertrophy and 21 controls].ResultsPAB

article thumbnail

Tenax Therapeutics Announces New U.S. Patent Covering the Use of Levosimendan in Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)

DAIC

Initially discovered and developed by Orion Corporation in Finland, intravenous levosimendan is approved in 60 countries outside the United States for use in hospitalized patients with acutely decompensated heart failure. Getty Images milla1cf Mon, 05/06/2024 - 10:48 May 6, 2024 — Tenax Therapeutics, Inc. ,

article thumbnail

Abstract 4120990: Classification of Echocardiography Videos Using TimeSformer for Detecting Incipient Heart Failure in Asymptomatic Patients with Normal Ejection Fraction and Patients with Heart Failure

Circulation

Circulation, Volume 150, Issue Suppl_1 , Page A4120990-A4120990, November 12, 2024. Background:Recent advancements have seen deep learning models help differentiate echocardiography images of patients with heart failure with preserved ejection fraction (HFpEF) from normal controls.